Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  INC Research Holdings Inc    

INC RESEARCH HOLDINGS INC
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Glancy Prongay & Murray LLP : Continues Investigation on Behalf of INC Research Holdings, Inc. Investors (INCR)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 09:01pm CEST

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of INC Research Holdings, Inc. (“INCR” or the “Company”) (NASDAQ: INCR) investors concerning the Company and its officers’ possible violations of federal securities law. To obtain information or aid in the investigation, please visit the INCR page on our website at https://www.glancylaw.com/case/inc-research-holdings-inc.

On November 9, 2017, INC Research reported its first financial results after combining with inVentiv Health. The Company’s combined results were negatively impacted by merger-related expenses, an impairment charge and increased amortization expenses. The price of INC Research stock fell significantly following the announcement.

On this news, INCR’s stock price fell nearly 30%, or $16.35 per share, to close at $41.15 per share on November 9, 2017, thereby injuring investors.

If you purchased INCR securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INC RESEARCH HOLDINGS INC
08/24SYNEOS HEALTH : Greg Rush joins Parexel as Executive VP & CFO
AQ
08/21SYNEOS HEALTH : Acquires Kinapse to Further Enhance End-to-End Capabilities
AQ
08/21SYNEOS HEALTH : acquires consulting firm to boost regulatory, safety, pharmacovi..
AQ
08/21SYNEOS HEALTH : acquires advisory & operational solutions provider Kinapse
AQ
08/20SYNEOS HEALTH, INC. : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
08/20Syneos Health™ Acquires Kinapse to Further Enhance End-to-End Capabilit..
GL
08/17Syneos Health to Present at the 2018 Baird Global Healthcare Conference
GL
08/17SYNEOS HEALTH : PAREXEL Announces Appointment of Two Key Executives
AQ
08/08SYNEOS HEALTH, INC. : Entry into a Material Definitive Agreement, Financial Stat..
AQ
08/08SYNEOS HEALTH : Announces Pricing of Secondary Offering of Common Stock
AQ
More news
News from SeekingAlpha
01/03INC Research CFO exiting post at April's end 
2017INC Research Holdings 2017 Q3 - Results - Earnings Call Slides 
2017INC Research's (INCR) CEO Alistair MacDonald on Q3 2017 Results - Earnings Ca.. 
2017Midday Gainers / Losers 
2017INC Research misses by $0.08, misses on revenue 
Financials ($)
Sales 2018 4 452 M
EBIT 2018 516 M
Net income 2018 33,0 M
Debt 2018 2 581 M
Yield 2018 -
P/E ratio 2018 156,35
P/E ratio 2019 34,85
EV / Sales 2018 1,72x
EV / Sales 2019 1,54x
Capitalization 5 067 M
Chart INC RESEARCH HOLDINGS INC
Duration : Period :
INC Research Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 56,2 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Alistair John Macdonald Chief Executive Officer & Director
Michael A. Bell Chairman
Jason Michael Meggs Chief Financial Officer & Executive Vice President
Kenneth F. Meyers Independent Director
Linda S. Harty Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INC RESEARCH HOLDINGS INC-5.39%5 067
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC31.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.81%14 156
SEATTLE GENETICS, INC.46.79%12 348